GGT and ALT: two liver enzymes covering two different jobs
GGT / ALT blood testing measures two liver enzymes that normally live inside liver tissue. GGT (gamma‑glutamyl transferase) is a membrane‑bound enzyme concentrated in cells lining the bile ducts, with smaller amounts in the liver, pancreas, and kidneys. ALT (alanine aminotransferase) sits inside liver cells (hepatocytes) in the cytosol. When these cells are disturbed, small amounts of these enzymes can appear in the bloodstream, which is why they are measured together.
Biologically, GGT helps recycle glutathione, the liver’s primary antioxidant buffer, supporting defense against oxidative stress and aiding the handling of bile components. ALT transfers amino groups between molecules (transamination), linking amino acid metabolism to energy production by converting alanine and related substrates into usable fuel for the liver. Considered together, GGT and ALT reflect two complementary aspects of liver biology: bile duct and membrane activity (GGT) and the metabolic workload and integrity of hepatocytes (ALT). This pairing offers a focused look at how liver cells are functioning and how bile is being managed within the liver-biliary system.
Why pairing GGT with ALT exposes the kind of liver stress at work
GGT (gamma‑glutamyl transferase) and ALT (alanine aminotransferase) are liver enzymes that reveal how well your liver’s cells and bile‑handling system are coping with daily work—processing nutrients, clearing toxins and drugs, managing glucose and lipids, and balancing hormones. Together they distinguish injury inside liver cells from strain in the bile ducts, which matters for digestion, vitamin absorption, and whole‑body metabolism.
Big picture: GGT and ALT sit at the crossroads of detoxification, bile flow, and energy metabolism. Persistent elevations correlate with insulin resistance, cardiovascular risk, and progression to fibrosis or cirrhosis, making these enzymes early sentinels of liver and metabolic health.
How the GGT/ALT pattern reads at low, balanced, and high values
Typical reference ranges are low—ALT roughly up to 30–40 and GGT up to 40–60—with women tending lower than men; healthy values usually sit in the low to middle part of these ranges. In children and teens, normal limits are age‑specific; pregnancy generally leaves GGT and ALT near non‑pregnant ranges.
When values sit at the low end, it usually reflects quiet turnover of liver cells and unobstructed bile flow. Very low ALT can occur with low vitamin B6 status or low muscle mass in older adults, but it rarely causes symptoms on its own. Low GGT is generally reassuring.
Rising ALT points to hepatocellular stress or injury—from fatty liver, viral hepatitis, alcohol, medications, or ischemia—often silent at first, sometimes with fatigue or right‑upper‑abdominal discomfort. Higher GGT signals biliary strain or enzyme induction, helping confirm the liver as the source of an elevated alkaline phosphatase; marked elevations may accompany cholestasis with itching, dark urine, and pale stools. Men more often show higher values; in pregnancy, elevations warrant careful evaluation. In teens and adults with excess weight, ALT commonly tracks fatty liver.
Low values usually reflect ALT being higher than GGT, pointing to predominant liver cell injury without strong enzyme induction. In practice this pattern aligns with fatty liver and insulin resistance, acute viral or toxic injury, or hypoxia-related damage. Men and younger adults often have higher ALT, making the ratio appear lower even with normal function.
Being in range suggests a balanced pattern: no clear signal of bile duct pressure or alcohol/medication enzyme induction, and no disproportionate hepatocyte leakage. Many experts view a low-to-mid ratio within the reference interval as consistent with metabolic stability and efficient hepatic processing.
High values usually reflect GGT being higher than ALT, indicating enzyme induction from alcohol exposure, certain medications, cholestasis (impaired bile flow), or systemic oxidative stress. This pattern correlates with higher cardiometabolic and cardiovascular risk profiles and may rise with age. In pregnancy, both enzymes are typically lower; a high ratio is less common and warrants context-specific interpretation.
Alcohol, enzyme-inducing drugs, and metabolic modifiers
Recent alcohol use, anticonvulsants and other enzyme-inducing drugs, obesity, diabetes, thyroid dysfunction, and smoking can shift the ratio. Vigorous exercise can transiently raise ALT. Reference ranges vary by lab, sex, age, and pregnancy; methods and timing of sampling also influence results.
Placing the GGT/ALT pattern inside a fuller hepatic panel
GGT and ALT are most informative when interpreted with ALP, bilirubin, AST, lipid and glucose markers, and imaging where indicated. Together they distinguish hepatocellular from cholestatic patterns and clarify metabolic, alcohol-related, or medication-induced liver stress.
FAQs
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Whitfield, J. B. (2001). Gamma glutamyl transferase. Critical Reviews in Clinical Laboratory Sciences, 38(4), 263-355. https://doi.org/10.1080/20014091084227
- Kwo, P. Y., Cohen, S. M., & Lim, J. K. (2017). ACG clinical guideline: Evaluation of abnormal liver chemistries. The American Journal of Gastroenterology, 112(1), 18-35. https://doi.org/10.1038/ajg.2016.517
- Newsome, P. N., Cramb, R., Davison, S. M., Dillon, J. F., Foulerton, M., Godfrey, E. M., Hall, R., Harrower, U., Hudson, M., Langford, A., Mackie, A., Mitchell-Thain, R., Sennett, K., Sheron, N. C., Verne, J., Walmsley, M., & Yeoman, A. (2018). Guidelines on the management of abnormal liver blood tests. Gut, 67(1), 6-19. https://doi.org/10.1136/gutjnl-2017-314924
- Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023). AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 77(5), 1797-1835. https://doi.org/10.1097/HEP.0000000000000323
- Long, Y., Zeng, F., Shi, J., Tian, H., & Chen, T. (2014). Gamma-glutamyltransferase predicts increased risk of mortality: A systematic review and meta-analysis of prospective observational studies. Free Radical Research, 48(6), 716-728. https://doi.org/10.3109/10715762.2014.902055






































.avif)
